title: [A long-term survival case of hepatocellular carcinoma recurrence after the patient received a living donor liver transplantation treated by combined modality therapy].
abstract: We report a case of hepatocellular carcinoma (HCC) recurrence after the patient received a living donor liver transplantation, which was treated by combined modality therapy. The patient survived for 67 months. A 61-year-old male was diagnosed as HCC with alcoholic cirrhosis and was transplanted the liver from a living donor. The number of tumors was about 50, the maximum tumor size was 3.3 cm and histology of the tumor was poorly differentiated hepatocellular carcinoma with portal invasion (Vp2). HCC recurred at the peritoneum 12 months after the liver transplantation and was surgically resected. Then, multiple HCC recurred in the liver graft and the patient was treated by systemic chemotherapy, and local therapy such as RFA, PEIT and TAE. Now 67 months after the transplantation, he additionally has a HCC metastasis to the spleen and lung and is treated by combined modality therapy. This case suggested that a combined modality therapy might have improved the survival of the patient after recurrence in the liver transplantation for advanced HCC.
authors.affiliation: Dept. of Surgery, Graduate School of Medicine, Osaka University.
authors.forename: Naoki
authors.initials: N
authors.lastname: Hama
authors.forename: Shigeru
authors.initials: S
authors.lastname: Marubashi
authors.forename: Keizo
authors.initials: K
authors.lastname: Dono
authors.forename: Shogo
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Chiwan
authors.initials: C
authors.lastname: Kim
authors.forename: Tadafumi
authors.initials: T
authors.lastname: Asaoka
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Takeda
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nagano
authors.forename: Koji
authors.initials: K
authors.lastname: Umeshita
authors.forename: Morito
authors.initials: M
authors.lastname: Monden
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Doki
authors.forename: Masaki
authors.initials: M
authors.lastname: Mori
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D003131:Combined Modality Therapy; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D016031:Liver Transplantation; D019520:Living Donors; D008175:Lung Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D000509:alpha-Fetoproteins